- Boston Scientific (BSX, Financial) reported Q1 2025 net sales of $4.663 billion, a 20.9% increase year-over-year.
- The Cardiovascular segment led growth with a 26.2% increase.
- The company projects full-year 2025 organic sales growth of 12-14%.
Boston Scientific Corporation (BSX) delivered a strong performance in Q1 2025, with net sales reaching $4.663 billion, marking a 20.9% reported growth from the previous year. This growth was primarily driven by an 18.2% increase in organic sales, as the company outperformed its guidance of 14-16% organic growth.
Regionally, the U.S delivered the most notable performance, recording a 31.1% increase in sales. This surge was complemented by strong showings in the Cardiovascular segment, which achieved a 26.2% growth, buoyed by Cardiology's 29.8% surge. Meanwhile, the MedSurg division reported an 11.7% increase.
Boston Scientific's strategic expansions included the acquisition of Bolt Medical and an agreement to acquire SoniVie, pending customary closing conditions. These steps are expected to bolster the company's portfolio in vascular disease treatment and ultrasound-based denervation for hypertension.
Looking ahead, Boston Scientific anticipates full-year 2025 organic sales growth of 12-14% and adjusted EPS between $2.87 and $2.94. For Q2 2025, the company projects an organic growth range of 13-15%, with adjusted EPS expected between $0.71 and $0.73.
